• Chan-Wei Tseng, Hao-Wei Teng, Chun-Chi Lin, Hao-Jan Lei, Jung-Jyh Hung, Wen-Yih Liang, Cheng-Yuan Hsia, Shu-Cheng Chou, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Yuan-Tzu Lan, Huann-Sheng Wang, Shung-Haur Yang, Wei-Shone Chen, Jen-Kou Lin, Jeng-Kai Jiang, Shih-Ching Chang, and Gar-Yang Chau.
• Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
• J Chin Med Assoc. 2023 Aug 1; 86 (8): 732739732-739.

BackgroundThe role of hepatectomy in a specific group of patients with synchronous colorectal cancer with liver metastases (SCRLM) and synchronous extrahepatic disease (SEHD) is still unclear. The aim of this study was to evaluate the efficacy of liver surgery and define the selection criteria for surgical candidates in patients with SCRLM + SEHD.MethodsBetween July 2007 and October 2018, 475 patients with colorectal cancer with liver metastases (CRLM) who underwent liver resection were retrospectively reviewed. Sixty-five patients with SCRLM + SEHD were identified and included in the study. Clinical pathological data of these patients were analyzed to evaluate the influence on survival. Important prognostic factors were identified by univariate and multivariate analyses. The risk score system and decision tree analysis were generated according to the important prognostic factors for better patient selection.ResultsThe 5-year survival rate of patients with SCRLM + SEHD was 21.9%. The most important prognostic factors were SCRLM number of more than five, site of SEHD other than the lung only, inability to achieve SCRLM + SEHD R0 resection, and BRAF mutation of cancer cells. The proposed risk score system and decision tree model easily discriminated between patients with different survival rates and identified the profile of suitable surgical patients.ConclusionLiver surgery should not be a contraindication for patients with SCRLM + SEHD. Patients with complete SCRLM + SEHD R0 resection, SCRLM number less than or equal to five, SEHD confined to the lung only, and wild-type BRAF could have favorable survival outcomes. The proposed scoring system and decision tree model may be beneficial to patient selection in clinical use.Copyright © 2023, the Chinese Medical Association.

20 keywords...

hide…